FI96095B - Förfarande för framställning av läkemedelspreparat med depåegenskaper - Google Patents
Förfarande för framställning av läkemedelspreparat med depåegenskaper Download PDFInfo
- Publication number
- FI96095B FI96095B FI873106A FI873106A FI96095B FI 96095 B FI96095 B FI 96095B FI 873106 A FI873106 A FI 873106A FI 873106 A FI873106 A FI 873106A FI 96095 B FI96095 B FI 96095B
- Authority
- FI
- Finland
- Prior art keywords
- release
- herb
- preparation
- drug
- pharmaceutical
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract description 9
- 229940079593 drug Drugs 0.000 title abstract description 8
- 238000002360 preparation method Methods 0.000 title abstract description 8
- 238000000034 method Methods 0.000 title description 13
- 238000013268 sustained release Methods 0.000 abstract description 4
- 239000012730 sustained-release form Substances 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 3
- 239000008280 blood Substances 0.000 abstract description 2
- 210000004369 blood Anatomy 0.000 abstract description 2
- 230000002459 sustained effect Effects 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 19
- 239000000203 mixture Substances 0.000 description 10
- 150000004665 fatty acids Chemical class 0.000 description 8
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 229940126601 medicinal product Drugs 0.000 description 6
- 239000001993 wax Substances 0.000 description 6
- 239000003921 oil Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 4
- -1 lauryl alcohol Chemical class 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 229960000278 theophylline Drugs 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 3
- IUGQFMIATSVYLK-UHFFFAOYSA-N benzyl 2-(4-hydroxyphenyl)acetate Chemical compound C1=CC(O)=CC=C1CC(=O)OCC1=CC=CC=C1 IUGQFMIATSVYLK-UHFFFAOYSA-N 0.000 description 3
- 229960003612 bunazosin hydrochloride Drugs 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 description 2
- 229920002545 silicone oil Polymers 0.000 description 2
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 1
- FPXKNYVSOKOLKD-BTJKTKAUSA-N (z)-but-2-enedioic acid;n-chloroaniline Chemical compound OC(=O)\C=C/C(O)=O.ClNC1=CC=CC=C1 FPXKNYVSOKOLKD-BTJKTKAUSA-N 0.000 description 1
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
- QNJVORDRXIGPJX-BTJKTKAUSA-N C(\C=C/C(=O)O)(=O)O.ClNCC1=CC=CS1 Chemical compound C(\C=C/C(=O)O)(=O)O.ClNCC1=CC=CS1 QNJVORDRXIGPJX-BTJKTKAUSA-N 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- JKRWZLOCPLZZEI-UHFFFAOYSA-N alpha-Trichloromethylbenzyl acetate Chemical compound CC(=O)OC(C(Cl)(Cl)Cl)C1=CC=CC=C1 JKRWZLOCPLZZEI-UHFFFAOYSA-N 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 1
- 229960000395 phenylpropanolamine Drugs 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (2)
1. Menetelmä jatkuvavaikutteisen, tabletti- tai raemuodossa olevan lääkevalmisteen valmistamiseksi, tunnettu siitä, että 5 yhtaikaa tai halutussa järjestyksessä sekoitetaan: (i) vesiliukoista rohdosta, jossa on ainakin yksi ryhmästä, johon kuuluvat bunatsosiinihydrokloridi, fenyylipropanoliami-ini, kloorifenyyliamiinimaleaatti ja teofylliini; (ii) lipidiainetta, joka on ainakin yksi ryhmästä joka käsit- io tää alifaattiset korkeammat rasvahapot, kuten steariinihapon, myristiinihapon ja palmitiinihapon; alifaattiset korkeammat alkoholit, kuten lauryylialkoholin, myristyylialkoholin ja stearyylialkoholin; korkeampien rasvahappojen esterit, kuten glyserinin monostearaatin, distearaatin ja tristearaatin ja 15 hydratun risiiniöljyn; vahat, kuten mehiläisvahan, karnauba- vahan, japanilaisen vahan ja valaan vahan; hiilivedyt, kuten parafiinin, mikrokiteisen vahan ja seresiinin sekä rasvahappojen sakkaroosiesterit; (iii) öljyä, joka on valittu ryhmästä joka käsittää oktyyli- 20 dodekyyliglyseridin, glyseriinimonokaprylaatin, silikoniöljyn ja migriolin. • · 9 96095
1. Förfarande för framställning av ett farnaceutiskt preparat med depäegenskaper i tablett- eller granulatform, känneteck 5 nat därav att man samtidigt eller i valfri ordning samman-blandar: i) en vattenlöslig substans väri minst en komponent är vald ur gruppen bestäende av bunazosinhydroklorid, fenylpro-panolamin, klorfenylaminmaleat, och teofyllin; 10 ii) en lipidsubstans, väri minst en komponent är vald ur gruppen vilken omfattar alifatiska högre fettsyror, säsom stearinsyra, myristinsyra och palmitinsyra; alifatiska högre alkoholer säsom laurylalkohol, myristylalkohol och steary-lalkohol; estrar av högre fettsyror säsom monostearat, dis-15 tearat och tristearat av glycerin samt hydrerad ricinolja; vaxer säsom bivax, karnaubavax, japanskt vax och valvax; kolväten säsom paraffin, mikrokristallint vax och ceresin samt sackarosestrar av fettsyror; iii) en olja vald ur gruppen vilken omfattar oktyldodekyl-20 glycerid, glycerinmonokaprylat, silikonolja och migriol.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP16786586 | 1986-07-18 | ||
| JP61167865A JPH0816066B2 (ja) | 1986-07-18 | 1986-07-18 | 持続性薬効製剤 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| FI873106A0 FI873106A0 (sv) | 1987-07-14 |
| FI873106A FI873106A (sv) | 1988-01-19 |
| FI96095B true FI96095B (sv) | 1996-01-31 |
| FI96095C FI96095C (sv) | 1996-05-10 |
Family
ID=15857516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI873106A FI96095C (sv) | 1986-07-18 | 1987-07-14 | Förfarande för framställning av läkemedelspreparat med depåegenskaper |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US5030455A (sv) |
| EP (1) | EP0254978B1 (sv) |
| JP (1) | JPH0816066B2 (sv) |
| KR (1) | KR960004857B1 (sv) |
| AT (1) | ATE71291T1 (sv) |
| CA (1) | CA1309656C (sv) |
| DE (1) | DE3775850D1 (sv) |
| DK (1) | DK174931B1 (sv) |
| ES (1) | ES2040228T3 (sv) |
| FI (1) | FI96095C (sv) |
| GR (1) | GR3003536T3 (sv) |
| NO (1) | NO179163C (sv) |
| PH (1) | PH25286A (sv) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01308232A (ja) * | 1988-06-03 | 1989-12-12 | Takeda Chem Ind Ltd | 固型医薬およびその製造法 |
| US4975312A (en) * | 1988-06-20 | 1990-12-04 | Foster-Miller, Inc. | Multiaxially oriented thermotropic polymer substrate for printed wire board |
| JP2681373B2 (ja) * | 1988-07-18 | 1997-11-26 | 塩野義製薬株式会社 | 徐放性製剤の製造法 |
| JP2794022B2 (ja) * | 1988-11-11 | 1998-09-03 | 三生製薬株式会社 | ブナゾシン或いはその塩類含有経皮適用製剤 |
| JP3195391B2 (ja) * | 1991-11-14 | 2001-08-06 | エスエス製薬株式会社 | 徐放性トラピジル錠 |
| GB2263910A (en) * | 1992-02-05 | 1993-08-11 | Co Ordinated Drug Dev | Direct compression tablet excipient |
| IL109460A (en) | 1993-05-10 | 1998-03-10 | Euro Celtique Sa | Controlled release formulation comprising tramadol |
| KR100354702B1 (ko) * | 1993-11-23 | 2002-12-28 | 유로-셀티크 소시에떼 아노뉨 | 약학조성물의제조방법및서방형조성물 |
| US5891471A (en) * | 1993-11-23 | 1999-04-06 | Euro-Celtique, S.A. | Pharmaceutical multiparticulates |
| ATE383848T1 (de) * | 1993-12-13 | 2008-02-15 | Avanir Pharmaceuticals | Formulierungen aus n-docosanol und saccharoseestern |
| US5843480A (en) * | 1994-03-14 | 1998-12-01 | Euro-Celtique, S.A. | Controlled release diamorphine formulation |
| GB9422154D0 (en) | 1994-11-03 | 1994-12-21 | Euro Celtique Sa | Pharmaceutical compositions and method of producing the same |
| US5965161A (en) | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
| JPH08143450A (ja) * | 1994-11-14 | 1996-06-04 | Taiyo Yakuhin Kogyo Kk | 徐放化製剤 |
| CA2233016C (en) * | 1995-09-25 | 2007-07-17 | Ashmont Holdings Limited | Anthelmintic macrocyclic lactone compositions |
| CA2252055C (en) | 1996-04-11 | 2007-01-16 | The University Of British Columbia | Fusogenic liposomes |
| DE19918325A1 (de) | 1999-04-22 | 2000-10-26 | Euro Celtique Sa | Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion |
| DE10041479A1 (de) * | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923 |
| DE10041478A1 (de) * | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung |
| KR20030024191A (ko) * | 2001-09-17 | 2003-03-26 | 주식회사 효성 | 알칼리 가용성 코폴리에스터 및 이의 제조방법 |
| ES2282492T3 (es) * | 2001-11-30 | 2007-10-16 | Pfizer Products Inc. | Composiciones farmaceuticas de liberacion controlada orales de 5,8,14-triazatetraciclo (10.3.1.0(2,11).0(4,9)-hexadeca-2(11)3,5,7,9-pentaeno. |
| US20040096498A1 (en) * | 2002-04-29 | 2004-05-20 | Alvin Kershman | Oral pharmaceutical delivery system with improved sustained release |
| JP5539539B2 (ja) * | 2010-12-08 | 2014-07-02 | アイダエンジニアリング株式会社 | 高強度焼結成形体の製造方法およびその製造装置 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2895881A (en) * | 1957-04-04 | 1959-07-21 | Wynn Pharmacal Corp | Quinidine gluconate sustained medication tablet |
| CH415963A (de) * | 1964-09-04 | 1966-06-30 | Wander Ag Dr A | Masse zur Herstellung von Tabletten mit protrahierter Wirkung |
| US3655864A (en) * | 1970-09-21 | 1972-04-11 | Smith Kline French Lab | Glyceryl tristerate and higher fatty acid mixture for improving digestive absorption |
| US4020159A (en) * | 1974-10-08 | 1977-04-26 | Apotheker A. Herbert K.G., Fabrik Pharmazeutischer Praparate Wiesbaden | Methods of and medications for treating cardiac disorders by using strophanthin |
| US4163777A (en) * | 1977-04-29 | 1979-08-07 | Lewis/Howe Company | Controlled antacid delivery form and method of treatment therewith |
| US4375468A (en) * | 1981-07-13 | 1983-03-01 | Verex Laboratories, Inc. | Constant order release aspirin composition and method of treating arthritis |
| JPS6143108A (ja) * | 1984-08-03 | 1986-03-01 | Nippon Shinyaku Co Ltd | 医薬品製剤及びその製造法 |
| ATE41740T1 (de) * | 1984-08-30 | 1989-04-15 | Rodisma Pharma Prod Gmbh | Verfahren zur retardierung von vitamin c und e. |
-
1986
- 1986-07-18 JP JP61167865A patent/JPH0816066B2/ja not_active Expired - Lifetime
-
1987
- 1987-07-14 FI FI873106A patent/FI96095C/sv not_active IP Right Cessation
- 1987-07-16 KR KR1019870007706A patent/KR960004857B1/ko not_active IP Right Cessation
- 1987-07-16 DE DE8787110297T patent/DE3775850D1/de not_active Expired - Lifetime
- 1987-07-16 EP EP87110297A patent/EP0254978B1/en not_active Expired - Lifetime
- 1987-07-16 ES ES198787110297T patent/ES2040228T3/es not_active Expired - Lifetime
- 1987-07-16 AT AT87110297T patent/ATE71291T1/de not_active IP Right Cessation
- 1987-07-17 NO NO872991A patent/NO179163C/no not_active IP Right Cessation
- 1987-07-17 DK DK198703731A patent/DK174931B1/da not_active IP Right Cessation
- 1987-07-17 PH PH8735554A patent/PH25286A/en unknown
- 1987-07-17 CA CA000542420A patent/CA1309656C/en not_active Expired - Lifetime
-
1989
- 1989-08-22 US US07/396,838 patent/US5030455A/en not_active Expired - Lifetime
-
1992
- 1992-01-09 GR GR910401578T patent/GR3003536T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ATE71291T1 (de) | 1992-01-15 |
| JPS6327439A (ja) | 1988-02-05 |
| FI96095C (sv) | 1996-05-10 |
| JPH0816066B2 (ja) | 1996-02-21 |
| DK174931B1 (da) | 2004-03-01 |
| DK373187D0 (da) | 1987-07-17 |
| NO179163B (no) | 1996-05-13 |
| KR960004857B1 (ko) | 1996-04-16 |
| DE3775850D1 (de) | 1992-02-20 |
| KR880001301A (ko) | 1988-04-22 |
| NO872991L (no) | 1988-01-19 |
| GR3003536T3 (sv) | 1993-03-16 |
| US5030455A (en) | 1991-07-09 |
| ES2040228T3 (es) | 1993-10-16 |
| NO872991D0 (no) | 1987-07-17 |
| NO179163C (no) | 1996-08-21 |
| DK373187A (da) | 1988-01-19 |
| PH25286A (en) | 1991-04-30 |
| FI873106A0 (sv) | 1987-07-14 |
| FI873106A (sv) | 1988-01-19 |
| EP0254978A1 (en) | 1988-02-03 |
| CA1309656C (en) | 1992-11-03 |
| EP0254978B1 (en) | 1992-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI96095B (sv) | Förfarande för framställning av läkemedelspreparat med depåegenskaper | |
| DE3879080T2 (de) | Pharmazeutische matrix mit verzoegerter freisetzung und verfahren. | |
| EP0533297B1 (en) | Controlled-release pharmaceutical formulations | |
| KR100203339B1 (ko) | 의약용 방출조절 매트릭스 | |
| DE69201793T2 (de) | Mehrschichtige zubereitung mit kontrollierter freisetzung. | |
| US5571533A (en) | Controlled-release mucoadhesive pharmaceutical composition for the oral administration of furosemide | |
| CN100379407C (zh) | 生产咀嚼分散片的方法 | |
| EP0255404B1 (en) | Sustained release ibuprofen formulation | |
| EP0142561A1 (en) | Long-acting nifedipine preparation | |
| US20020102300A1 (en) | Pharmaceuticals formulation | |
| US4837032A (en) | Theophylline sustained release tablet | |
| KR930008956B1 (ko) | 서방형 이부프로펜 제제의 제조방법 | |
| FR2568472A1 (fr) | Preparations pharmaceutiques retard et procede pour les fabriquer | |
| KR20070119700A (ko) | 페노피브레이트 및 계면 활성제 혼합물을 함유하는 제제 | |
| AU748396B2 (en) | Composition | |
| JP4853818B2 (ja) | イブプロフェン及び塩酸アンブロキソール含有固形製剤 | |
| JPH069381A (ja) | イブプロフェン含有軟カプセル剤 | |
| EP0684042B1 (en) | Oral solid pharmaceutical compositions containing as active ingredient gemfibrozil and process for preparing them | |
| EP1075253B1 (de) | Wirkstoff enthaltende orale oder mucosale zubereitung mit steuerbarer wirkstofffreisetzung und ihre verwendung | |
| EP2934590A1 (de) | Magnesiumhydroxidcarbonat als träger in pharmazeutischen zubereitungen mit verbesserter wirkstofffreisetzung | |
| KR100558070B1 (ko) | 가용성 덱시부프로펜의 연질캅셀제 조성물 및 그의 제조방법 | |
| WO2004075817A2 (en) | Suspendable pharmaceutical composition | |
| KR900000854B1 (ko) | 생약 수침 건조엑스의 마이크로 캅셀의 제조방법 | |
| Baert et al. | Influence of feeding on the bioavailability of ronidazole prolonged‐release formulations in pigeons | |
| KR20040106915A (ko) | 가용성 이부프로펜의 연질캅셀제 조성물 및 그의 제조방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| BB | Publication of examined application | ||
| FG | Patent granted |
Owner name: EISAI CO., LTD. |
|
| MA | Patent expired |